To own TG Therapeutics, you need to be comfortable with a story built around BRIUMVI execution, heavy upfront manufacturing spend, and a push into broader autoimmune use. The analyst consensus Narrative on Simply Wall St leans on that arc. The latest quarter shows strong revenue alongside much smaller net income, so the near term swing factor remains whether management can keep scaling BRIUMVI without letting costs erode profitability.
The biggest operational risk right now sits in those manufacturing and subcutaneous BRIUMVI investments. If they fail to convert into durable demand, free cash flow can stay tight and margin improvement may be slower. The raised 2026 revenue guidance signals confidence in current demand but does not, by itself, remove the cost and governance overhangs flagged in recent risk commentary.
The most directly relevant update is TG Therapeutics lifting full year 2026 global revenue guidance to about US$1b. That sits alongside Q3 revenue of US$259.94 million and net income of US$55.46 million. In the short term, the raised outlook supports the idea that BRIUMVI demand is tracking ahead of earlier internal expectations, even as earnings per share remain well below last year.
For catalysts, that new target ties back to the subcutaneous BRIUMVI push and potential label changes that could simplify dosing. Those projects require significant spend and are already contributing to margin pressure, which is why the narrative still hinges on execution. If you are following TGTX, the key watchpoints are quarterly operating costs, cash generation versus debt, and how quickly any new formulations start to contribute to reported revenue.
TG Therapeutics' outlook projects US$1.9b revenue and US$612.2 million earnings by 2029. That path assumes 27.8% yearly revenue growth and an earnings increase of about US$506.1 million from current earnings of US$106.1 million.
Uncover why TG Therapeutics' fair value indicates a 21% potential upside to its current price that may not last much longer.
Some of the lowest TG Therapeutics forecasts leaned hard into BRIUMVI concentration risk, with a more cautious group penciling in about US$1.7b revenue and US$676.0 million earnings by 2029. Those views were set before this guidance raise, so if you lean toward that more pessimistic camp, this latest update may prompt a fresh look.
Explore 4 other TG Therapeutics fair value estimates, including one that suggests it could be worth just $69.43.
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
If the TG Therapeutics story has sharpened your thinking about risk, reward, and concentration in a single therapy, it can be useful to line it up against a wider watchlist built from different angles on quality and balance sheet strength.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com